reports
Indkaldelse til ordinær generalforsamling 2025
Indkaldelse til ordinær generalforsamling 2025 MEDDELELSE NR. 293 17. september 2025 Indkaldelse til ordinær generalforsamling Vedlagt offentliggøres selskabets indkaldelse til ordinær generalforsamling, som afholdes torsdag den 9. oktober 2025 kl. 17.30. Generalforsamlingen afholdes hos Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød. Yderligere oplysninger Kim Nicolajsen, CFO Telefon (+45) 48 13 10 20 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrumenter til celletælling og en lang række andre målinger. ChemoMetecs instrumenter markedsf...
Notice of Annual General Meeting 2025
Notice of Annual General Meeting 2025 ANNOUNCEMENT NO. 293 17 September 2025 Notice of Annual General Meeting Notice is hereby given of the Annual General Meeting, which will be held on Thursday 9 October 2025 at 5.30 p.m. The general meeting will be held at Nordsjællands KonferenceCenter, Gydevang 39-41, 3450 Allerød Additional info Kim Nicolajsen, CFO Telefon (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, bi...
Årsrapport 2024/25 - Vækst i omsætning og EBITDA
Årsrapport 2024/25 - Vækst i omsætning og EBITDA MEDDELELSE NR. 292 11. september 2025 Årsrapport 2024/25 (1. juli 2024 - 30. juni 2025) Vækst i omsætning og EBITDA ChemoMetecs omsætning steg i 2024/25 med 22% til DKK 495,6 mio., og driftsresultatet (EBITDA) viste en fremgang på 39% og blev på DKK 258,0 mio. Den positive udvikling i omsætningen afspejler en stigning i salget af både instrumenter, forbrugsvarer og serviceydelser. Lanceringen af de nye XcytoMatic-produkter forløber tilfredsstillende. ”Samtidig med vores store fokus på igen at skabe vækst i den eksisterende forret...
Annual Report 2024/25 - Growing revenue and EBITDA
Annual Report 2024/25 - Growing revenue and EBITDA ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating profit (EBITDA) increased by 39% to DKK 258.0 million. The positive revenue performance reflected an increase in sales of both instruments, consumables and services. The launch of the new XcytoMatic products is proceeding as planned. “Along with our strong focus on creating renewed momentum in our existing business, we spent considerable re...
Forventninger til regnskabsåret 2025/26
Forventninger til regnskabsåret 2025/26 MEDDELELSE NR. 291 11. september 2025 Forventninger til regnskabsåret 2025/26 ChemoMetec har i dag godkendt årsrapporten for 2024/25, herunder forventningerne til 2025/26, som vurderes at udgøre intern viden. ChemoMetec forventer i 2025/26 en omsætning i niveauet DKK 545-565 mio. (2024/25: DKK 495,6 mio.) og et driftsresultat (EBITDA) i niveauet DKK 295-315 mio. (2024/25: DKK 258,0 mio.). Årsrapporten for 2024/25 offentliggøres samtidig med denne meddelelse, og der er heri redegjort for forudsætningerne for forventningerne til 2025/26 (s. 39-4...
Guidance for the 2025/26 financial year
Guidance for the 2025/26 financial year ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside information. For 2025/26, ChemoMetec expects revenue in the range of DKK 545-565 million (2024/25: DKK 495.6 million) and EBITDA in the range of DKK 295-315 million (2024/25: DKK 258.0 million). The annual report for 2024/25, which is released along with this announcement, sets out the underlying assumptions applied in the preparation of the guidan...
Foreløbige tal for omsætningen i regnskabsåret 2024/25
Foreløbige tal for omsætningen i regnskabsåret 2024/25 MEDDELELSE NR. 290 1. juli 2025 Foreløbige tal for omsætningen i regnskabsåret 2024/25 På baggrund af de foreløbige regnskabstal forventes ChemoMetec at omsætte omkring DKK 496 mio. i regnskabsåret 2024/25, mod tidligere udmeldt DKK 470-490 mio. ChemoMetecs årsrapport for 2024/25 forventes offentliggjort den 11. september 2025. Yderligere oplysninger Martin Helbo Behrens, CEOTelefon: (+45) 48 13 10 20 Kim Nicolajsen, CFOTelefon (+45) 48 13 10 20 Om ChemoMetec A/S ChemoMetec udvikler, producerer og markedsfører instrum...
Preliminary revenue figures for the 2024/25 financial year
Preliminary revenue figures for the 2024/25 financial year ANNOUNCEMENT NO. 290 1 July 2025 Preliminary revenue figures for the 2024/25 financial year Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million for the financial year 2024/25, against the previously announced DKK 470-490 million. ChemoMetec’s annual report for 2024/25 is scheduled to be released on 11 September 2025. Additional information Martin Helbo Behrens, CEOTel.: (+45) 48 13 10 20 Kim Nicolajsen, CFOTel.: (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec deve...
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK640.00) - Solid Q3, but with mixed elements
With c26% revenue growth, Q3 was stronger than expected, with a solid beat on recurring revenue lines, although instruments fell just shy of our forecast, mainly related to new product launches that, despite a significant rise in customer validations in progress, take time. The maintained guidance implies only c5% YOY growth in Q4, but we believe management is being conservative. We reiterate our BUY and DKK640 target price.
Fortsat vækst i omsætning og driftsresultat
Fortsat vækst i omsætning og driftsresultat Periodemeddelelse for 3. kvartal 2024/25 (1. januar - 31. marts 2025) Fortsat vækst i omsætning og driftsresultat Omsætningen steg i 3. kvartal med 26% til DKK 124,2 mio. fra DKK 98,9 mio. i samme periode sidste år. Væksten var især drevet af salg af produkter knyttet til NC-platformen som følge af fremgang i aktiviteten hos kunder med igangværende kliniske forsøg og godkendte terapier. Udviklingen afspejler en fortsat fremgang i omsætningen af både instrumenter, forbrugsvarer og services. Lanceringen af de nye XcytoMatic-produkter forløber fort...
Continued growth in revenue and operating profit
Continued growth in revenue and operating profit Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9 million in the year-earlier period. Growth was driven primarily by sales of products related to the NC platform, reflecting increased activity levels for customers with ongoing clinical trials and approved therapies. The Q3 performance reflected continued growth in sales of both instruments, consumables and services. The launch of the new XcytoM...
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK640.00) - Likely solid Q3 but no pre-release
We previously expected ChemoMetec to have raised its full-year guidance ahead of the Q3 results, but assume the weaking USD and greater uncertainty from tariffs led it to refrain. We still expect a solid Q3, helped by new product launches, while in general we expect tariffs to have minimal effect on its costs, considering its location of production and high gross margin. We reiterate our BUY, but have lowered our target price to DKK640 (675).
ChemoMetec A S: 1 director
A director at ChemoMetec A S bought 865 shares at 574.030DKK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Notification of managers' transactions
Notification of managers' transactions ANNOUNCEMENT NO. 288 10 February 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 1...
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK675.00) - Growth that counts
ChemoMetec again reported solid results, well above expectations, despite its raised guidance in January, which looks increasingly conservative. It was notably a broad-based beat, with all product segments exceeding expectations. We are especially encouraged by the continued solid rebound in Instrument sales, helped by recent product launches. Margins were also strong (especially versus consensus), suggesting robust operating leverage. We reiterate our BUY and have increased our target price to ...
1. halvår 2024/25 - Godt første halvår med vækst i både omsætning og d...
1. halvår 2024/25 - Godt første halvår med vækst i både omsætning og driftsresultat MEDDELELSE NR. 2875. februar 2025 Godt første halvår med vækst i både omsætning og driftsresultat Martin Helbo Behrens, CEO: Fremgangen er fortsat i 2. kvartal 2024/25, og i 1. halvår steg omsætningen til DKK 251,5 mio., svarende til en vækst på 26% sammenlignet med samme periode sidste år. Væksten var blandt andet drevet af enkelte større ordrer på de nye XcytoMatic-instrumenter i kølvandet på de igangsatte kundevalideringer i foråret 2024. I 1. halvår har vi samtidig fastholdt vores kommercielle fo...
Interim report 2024/25 - Solid H1 performance driven by growth in both...
Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue for the first half of the year was up to DKK 251.5 million, a year-on-year increase of 26%. Growth was supported by a few large orders for the new XcytoMatic instruments in the wake of the customer validations initiated in the spring of 2024. Concurrently, we maintained our commercial focus in the f...
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK615.00) - Counting on more increases
Following a string of guidance increases, we expect a solid Q2 on good instrument sales momentum, driven by new product launches and recovering end markets. We believe new management’s latest guidance is still too cautious and is likely to be raised again. We reiterate our BUY and have raised our target price to DKK615 (540).
Upgrade of revenue and operating profit guidance
Upgrade of revenue and operating profit guidance ANNOUNCEMENT NO. 286 10 January 2025 Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales and order intake. The positive development is supported by the strengthening of the US dollar and continuous optimisation of operating costs. Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 470-490 million range, up from DKK 460-475 million in the most recent guidance, and EBITDA in the DKK 250-260 mill...
Major shareholder announcement – AIM International Mutual Funds
Major shareholder announcement – AIM International Mutual Funds ANNOUNCEMENT NO. 287 9 December 2024 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 4 December 2024, decreased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to below 5%, and that the holding thus is below the 5 per cent limit in section...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.